The novel bone alkaline phosphatase B1x isoform in children with kidney disease

Pediatric Nephrology

Volumn 21, Issue 11, 2006, Pages 1723-1729

  Swolin Eide, Diana ^a   Hansson, Sverker ^a   Larsson, Lasse ^b   Magnusson, Per ^b,c  

^a QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^c Bone and Mineral Metabolic Unit   (Sweden)

Author keywords

Chronic kidney disease; Growth hormone; Parathyroid hormone; Pediatric; Renal osteodystrophy

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALFACALCIDOL; ALKALINE PHOSPHATASE; ALKALINE PHOSPHATASE BONE ISOENZYME; ALKALINE PHOSPHATASE ISOENZYME; BICARBONATE; CALCIUM CARBONATE; CARBOXY TERMINAL TELOPEPTIDE; OSTEOCALCIN; OSTEOPROTEGERIN; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PROCOLLAGEN; RECOMBINANT GROWTH HORMONE;

ACCURACY; ADOLESCENT; ADULT; AGE; ARTICLE; CHEMOLUMINESCENCE; CHILD; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DISEASE CLASSIFICATION; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULUS FILTRATION RATE; GROWTH RETARDATION; HEMODIALYSIS; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MALE; MORPHOMETRICS; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RENAL OSTEODYSTROPHY;

ADOLESCENT; ADULT; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE AND BONES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; KIDNEY DISEASES; MALE; OSTEOPROTEGERIN; PARATHYROID HORMONE; PROTEIN ISOFORMS;

EID: 33748743185     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-006-0231-2     Document Type: Article

References (53)

1. Hruska K (2000) Pathophysiology of renal osteodystrophy. Pediatr Nephrol 333:166-174
2. Kuizon BD, Salusky IB, (2003) Renal osteodystrophy: Pathogenesis, diagnosis, and treatment. In: Glorieux FH, Pettifor JM, Jüppner H (Eds.) Pediatric bone. Biology and diseases. Academic Press, London, pp 679-701
3. Kuizon BD, Salusky IB (1999) Growth retardation in children with chronic renal failure. J Bone Miner Res 14:1680-1690
4. Salusky IB, Ramirez JA, Oppenheim W, Gales B, Segre GV, Goodman WG (1994) Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. Kidney Int 45:253-258
5. Ziolkowska H, Panczyk-Tomaszewska M, Debinski A, Polowiec Z, Sawicki A, Sieniawska M (2000) Bone biopsy results and serum bone turnover parameters in uremic children. Acta Paediatr 89:666-671
6. Ureña P, de Vernejoul M-C (1999) Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int 55:2141-2156
7. Rix M, Andreassen H, Eskildsen P, Langdahl B, Olgaard K (1999) Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int 56:1084-1093
8. Bervoets ARJ, Spasovski GB, Behets GJ, Dams G, Polenakovic MH, Zafirovska K, Van Hoof VO, De Broe ME, D'Haese PC (2003) Useful biochemical markers for diagnosing renal osteodystrophy in predialysis endstage renal failure patients. Am J Kidney Dis 41:997-1007
9. Slatopolsky E, Finch J, Clay P, Martin D, Sicard G, Singer G, Gao P, Cantor T, Dusso A (2000) A novel mechanism for skeletal resistance in uremia. Kidney Int 58:753-761
10. Gao P, Scheibel S, D'Amour P, John MR, Rao SD, Schmidt-Gayk H, Cantor TL (2001) Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: Implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res 16:605-614
11. Inaba M, Nakatsuka K, Imanishi Y, Watanabe M, Mamiya Y, Ishimura E, Nishizawa Y (2004) Technical and clinical characterization of the bioPTH (1-84) immunochemiluminometric assay and comparison with a secondgeneration assay for parathyroid hormone. Clin Chem 50:385-390
12. Lee SK, Lorenzo JA (1999) Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: Correlation with osteoclast-like cell formation. Endocrinology 140:3552-3561
13. Rogers A, Eastell R (2005) Circulating osteoprotegerin and receptor activator for nuclear factor kB ligand: Clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 90:6323-6331
14. Magnusson P, Degerblad M, Sääf M, Larsson L, Thorén M (1997) Different responses of bone alkaline phosphatase isoforms during recombinant insulin-like growth factor-I (IGF-I) and during growth hormone therapy in adults with growth hormone deficiency. J Bone Miner Res 12:210-220
15. Whyte MP (1994) Hypophosphatasia and the role of alkaline phosphatase in skeletal mineralization. Endocr Rev 15:439-461
16. Johnson KA, Hessle L, Vaingankar S, Wennberg C, Mauro S, Narisawa S, Goding JW, Sano K, Millán JL, Terkeltaub R (2000) Osteoblast tissue-nonspecific alkaline phosphatase antagonizes and regulates PC-1. Am J Physiol Regul Integr Comp Physiol 279:R1365-R1377
17. Magnusson P, Löfman O, Larsson L (1992) Determination of alkaline phosphatase isoenzymes in serum by high-performance liquid chromatography with postcolumn reaction detection. J Chromatogr 576:79-86
18. Magnusson P, Löfman O, Larsson L (1993) Methodological aspects on separation and reaction conditions of bone and liver alkaline phosphatase isoform analysis by high-performance liquid chromatography. Anal Biochem 211:156-163
19. Magnusson P, Ärlestig L, Paus E, Di Mauro S, Testa MP, Stigbrand T, Farley JR, Nustad K, Millán JL (2002) Monoclonal antibodies against tissue-nonspecific alkaline phosphatase. Report of the ISOBM TD9 workshop. Tumour Biol 23:228-248
20. Magnusson P, Farley JR (2002) Differences in sialic acid residues among bone alkaline phosphatase isoforms: A physical, biochemical, and immunological characterization. Calcif Tissue Int 71:508-518
21. Magnusson P, Häger A, Larsson L (1995) Serum osteocalcin and bone and liver alkaline phosphatase isoforms in healthy children and adolescents. Pediatr Res 38:955-961
22. Magnusson P, Sharp CA, Magnusson M, Risteli J, Davie MWJ, Larsson L (2001) Effect of chronic renal failure on bone turnover and bone alkaline phosphatase isoforms. Kidney Int 60:257-265
23. Magnusson P, Sharp CA, Farley JR (2002) Different distributions of human bone alkaline phosphatase isoforms in serum and bone tissue extracts. Clin Chim Acta 325:59-70
24. Levey AS, Eckardt K-U, Tsukamoto Y, Levin A, Coresh J, Rossert J, de Zeeuw D, Hostetter TH, Lameire N, Eknoyan G (2005) Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 67:2089-2100
25. Schwartz GJ, Haycock GB, Edelmann Jr CM, Spitzer A (1976) A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58:259-269
26. Nussbaum SR, Zahradnik RJ, Lavigne JR, Brennan GL, Nozawa-Ung K, Kim LY, Keutmann HT, Wang C-A, Potts Jr JT, Segre GV (1987) Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 33:1364-1367
27. Szulc P, Hofbauer LC, Heufelder AE, Roth S, Delmas PD (2001) Osteoprotegerin serum levels in men: Correlation with age, estrogen, and testosterone status. J Clin Endocrinol Metab 86:3162-3165
28. Masters PW, Jones RG, Purves DA, Cooper EH, Cooney JM (1994) Commercial assays for serum osteocalcin give clinically discordant results. Clin Chem 40:358-363
29. Melkko J, Kauppila S, Niemi S, Risteli L, Haukipuro K, Jukkola A, Risteli J (1996) Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin Chem 42:947-954
30. Rosenquist C, Fledelius C, Christgau S, Pedersen BJ, Bonde M, Qvist P, Christiansen C (1998) Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bonerelated degradation products from C-terminal telopeptides of type I collagen. Clin Chem 44:2281-2289
31. Sassi M-L, Eriksen H, Risteli L, Niemi S, Mansell J, Gowen M, Risteli J (2000) Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: Loss of antigenicity by treatment with cathepsin K. Bone 26:367-373
32. Halleen JM, Alatalo SL, Suominen H, Cheng SL, Janckila AJ, Väänänen HK (2000) Tartrate-resistant acid phosphatase 5b: A novel serum marker of bone resorption. J Bone Miner Res 15:1337-1345
33. Cioffi M, Corradino M, Gazzerro P, Vietri MT, Di Macchia C, Contursi A, Colicigno R, Catalano T, Molinari AM (2000) Serum concentrations of intact parathyroid hormone in healthy children. Clin Chem 46:863-864
34. Buzi F, Maccarinelli G, Guaragni B, Ruggeri F, Radetti G, Meini A, Mazzolari E, Cocchi D (2004) Serum osteoprotegerin and receptor activator of nuclear factors kB (RANKL) concentrations in normal children and in children with pubertal precocity, Turner's syndrome and rheumatoid arthritis. Clin Endocrinol 60:87-91
35. Tarallo P, Henny J, Fournier B, Siest G (1990) Plasma osteocalcin: biological variations and reference limits. Scand J Clin Lab Invest 50:649-655
36. van der Sluis IM, Hop WC, van Leeuwen JPTM, Pols HAP, de Muinck Keizer-Schrama SMPF (2002) A crosssectional study on biochemical parameters of bone turnover and vitamin D metabolites in healthy dutch children and young adults. Horm Res 57:170-179
37. Crofton PM, Evans N, Taylor MRH, Holland CV (2002) Serum CrossLaps: pediatric intervals from birth to 19 years of age. Clin Chem 48:671-673
38. Alatalo SL, Ivaska KK, Waguespack SG, Econs MJ, Väänänen HK, Halleen JM (2004) Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schönberg disease (type II autosomal dominant osteopetrosis). Clin Chem 50:883-890
39. Magnusson P, Larsson L, Magnusson M, Davie MWJ, Sharp CA (1999) Isoforms of bone alkaline phosphatase: Characterization and origin in human trabecular and cortical bone. J Bone Miner Res 14:1926-1933
40. Ohlsson C, Bengtsson B-Å, Isaksson OGP, Andreassen TT, Slootweg MC (1998) Growth hormone and bone. Endocr Rev 19:55-79
41. Haffner D, Schaefer F, Nissel R, Wudie;hl E, Tönshoff B, Mehls O (2000) Effect of growth hormone treatment on the adult height of children with chronic renal failure. German study group for growth hormone treatment in chronic renal failure. N Engl J Med 343:923-930
42. Kaskel F (2003) Chronic renal disease: A growing problem. Kidney Int 64:1141-1151
43. Lepage R, Roy L, Brossard J-H, Rousseau L, Dorais C, Lazure C, D'Amour P (1998) A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem 44:805-809
44. Friedman PA (2004) PTH revisited. Kidney Int 66(Suppl 91):S13-S19
45. Rogers A, Saleh G, Hannon RA, Greenfield D, Eastell R (2002) Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. J Clin Endocrinol Metab 87:4470-4475
46. Coen G, Ballanti P, Balducci A, Calabria S, Fischer MS, Jankovic L, Manni M, Morosetti M, Moscaritolo E, Sardella D, Bonucci E (2002) Serum osteoprotegerin and renal osteodystrophy. Nephrol Dial Transplant 17:233-238
47. Kazama JJ, Shigematsu T, Yano K, Tsuda E, Miura M, Iwasaki Y, Kawaguchi Y, Gejyo F, Kurokawa K, Fukagawa M (2002) Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis 39:525-532
48. Kazama JJ (2004) Osteoprotegerin and bone mineral metabolism in renal failure. Curr Opin Nephrol Hypertens 13:411-415
49. Risteli J, Risteli L (1999) Products of bone collagen metabolism. In: Seibel MJ, Robins SP, Bilezikian JP (Eds.) Dynamics of bone and cartilage metabolism: Principles and clinical applications. Academic Press, London, pp 275-287
50. Bruder SP, Horowitz MC, Mosca JD, Haynesworth SE (1997) Monoclonal antibodies reactive with human osteogenic cell surface antigens. Bone 21:225-235
51. Ivaska KK, Hentunen TA, Väräniemi J, Ylipahkala H, Pettersson K, Väänänen HK (2004) Release of intact and fragmented osteocalcin molecules from bone matrix during bone resorption in vitro. J Biol Chem 279:18361-18369
52. Charhon SA, Delmas PD, Malaval L, Chavassieux PM, Arlot M, Chapuy M-C, Meunier PJ (1986) Serum bone Gla-protein in renal osteodystrophy: comparison with bone histomorphometry. J Clin Endocrinol Metab 63:892-897
53. Ureña P, Ferreira A, Kung VT, Morieux C, Simon P, Ang KS, Souberbielle JC, Segre GV, Drüeke TB, de Vernejoul MC (1995) Serum pyridinoline as a specific marker of collagen breakdown and bone metabolism in hemodialysis patients. J Bone Miner Res 10:932-939